The percentage of NKT-like cells is suggested to be a predictive biomarker for COVID-19 severity and patient outcome [2,21], although in another study alterations in circulating CD56+ T cell frequency were shown to be independent of COVID-19 severity [22,23]. This evidence concerns the gene NCAM1 and COVID-19.